The consensus panel has recognized several systemic therapies for unresectable stage IV melanoma, including high-dose IL-2, ipilimumab and, in BRAF-mutated tumors, vemurafenib, dabrafenib (BRAF inhibitors) and trametinib (MEK inhibitor), as well as referral for ongoing clinical trials. This evidence concerns the gene MAP2K7 and melanoma.